RPE Cell Therapy Shows Improvements in Early GA With AMD
RG6501 (OpRegen) allogeneic retinal pigment epithelium (RPE) cell therapy has continued to be well-tolerated in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in extended follow-up data from a phase 1/2 trial …